Aly M. Abdelrahman

Muscat, MA 123, Oman

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study.

Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study.

Journal: British journal of clinical pharmacology

Published: November 20, 2025

The effects of sacubitril/valsartan compared to valsartan in experimentally induced chronic kidney disease.

The effects of sacubitril/valsartan compared to valsartan in experimentally induced chronic kidney disease.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: November 03, 2025

Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation.

Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation.

Journal: Biology

Published: August 10, 2025

Effect of Riociguat on Adenine-Induced Chronic Kidney Disease in Rats.

Effect of Riociguat on Adenine-Induced Chronic Kidney Disease in Rats.

Journal: Biology

Published: December 14, 2024

Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side.

Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side.

Journal: Journal of clinical medicine

Published: November 13, 2024

Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats.

Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats.

Journal: Toxicology reports

Published: August 12, 2024

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side.

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side.

Journal: Journal of clinical medicine

Published: January 08, 2024

Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital.

Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: November 16, 2023

Nephroprotective effects of diminazene on doxorubicin-induced acute kidney injury in rats.

Nephroprotective effects of diminazene on doxorubicin-induced acute kidney injury in rats.

Journal: Toxicology reports

Published: October 07, 2023

Potentially Harmful Drug-Drug Interactions and Their Associated Factors Among Hospitalized Cardiac Patients: A Cross-Sectional Study.

Potentially Harmful Drug-Drug Interactions and Their Associated Factors Among Hospitalized Cardiac Patients: A Cross-Sectional Study.

Journal: Drugs - real world outcomes

Published: April 26, 2023

Access- and non-access-related infections among patients receiving haemodialysis: Experience of an academic centre in Oman.

Access- and non-access-related infections among patients receiving haemodialysis: Experience of an academic centre in Oman.

Journal: IJID regions

Published: December 01, 2022

The effect of diminazene, an angiotensin-converting enzyme 2 activator, on adenine-induced chronic kidney disease in rats.

The effect of diminazene, an angiotensin-converting enzyme 2 activator, on adenine-induced chronic kidney disease in rats.

Journal: Fundamental & clinical pharmacology

Published: February 17, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026